
“Promoter exodus meets DII lifeline in debt-free pharma shell.”
No clear market view today
The signals we track (volume, delivery, price trend, deals, breadth and flows) aren't aligned for BROOKS today. That isn't bearish, just inconclusive.
50-day SMA is below 200-day SMA (bearish long-term trend)
India-specific risk checks.
Four fundamentals lenses on the company itself: valuation, growth, returns & margins, and financial health, judged against the stock's sector. A separate read from the Market Setup above.
Valuations look stretched
₹1,000 invested here buys about ₹72 of annual profit. A cheaper stock would buy more.
Steady growth
Excellent returns and margins
Strong balance sheet
Data as of 18 Sept 2026, 11:10 am